drugset / Trial / NCT01333462
Safety and Immunogenicity Study of Inactivated Nasal Influenza Vaccine NB-1008
RandomizedParallel-groupSingle-blindPrevention
Summary
The purpose of this study is to test the safety and immune response of a new intranasal vaccine against influenza, called NB-1008. The vaccine is composed of a licensed vaccine that is normally given as an injection, called Fluzone, and an adjuvant (additive that helps a vaccine work better), called W805EC.
Timeline
- Start
- 2009-03
- Primary completion
- 2009-08
- Completion
- 2010-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | NB-1008 | Vaccine | 4 ug | Intranasal |
| Subject | NB-1008 | Vaccine | 10 ug | Intranasal |
| Subject | NB-1008 | Vaccine | 5 % | Intranasal |
| Subject | NB-1008 | Vaccine | 10 % | Intranasal |
| Subject | NB-1008 | Vaccine | 15 % | Intranasal |
| Subject | NB-1008 | Vaccine | 20 % | Intranasal |
Indications
No indication recorded.